Cirrhosis can be present quietly for years, yet its complications often surface fast, like fatigue in 60 to 85% of patients and ascites developing in half of decompensated cases within 2 years. Globally, cirrhosis contributed 1.32 million deaths in 2017, and in the US the age adjusted mortality rate has climbed from 9.2 per 100,000 in 2000 to 10.3 per 100,000 in 2015. These figures also diverge sharply by condition and cause, from variceal bleeding risk to how much heavy alcohol use multiplies the odds.
Key Takeaways
- Fatigue occurs in 60-85% of cirrhosis patients
- Ascites develops in 50% of decompensated cirrhosis cases within 2 years
- Hepatic encephalopathy prevalence: 30-40% in cirrhosis patients
- Globally, cirrhosis accounts for 1.32% (1.27-1.37) of all deaths worldwide in 2017, equating to 1,320,000 deaths
- In the US, the age-adjusted cirrhosis mortality rate increased from 9.2 per 100,000 in 2000 to 10.3 per 100,000 in 2015
- Prevalence of cirrhosis in the general US adult population is estimated at 0.27% (688,000 persons)
- Alcohol is responsible for 60% of cirrhosis cases in Western Europe
- Chronic hepatitis C infection leads to cirrhosis in 20-30% of cases over 20-30 years
- Non-alcoholic steatohepatitis (NASH) progresses to cirrhosis in 20% of cases
- Abstinence from alcohol improves survival by 2-fold in alcoholic cirrhosis
- Beta-blockers reduce variceal bleeding risk by 40-50%
- Diuretics (spironolactone + furosemide) control ascites in 90% initially
- 5-year mortality in decompensated cirrhosis is 50-70%
- Hepatocellular carcinoma (HCC) develops in 1-8% annually in cirrhotics
- 1-year survival post-variceal bleed: 65% without rebleeding control
Cirrhosis is common and deadly, with frequent complications like fatigue, ascites, and encephalopathy.
Related reading
01 · Category
Clinical Features30 stats
01
Fatigue occurs in 60-85% of cirrhosis patients
02
Ascites develops in 50% of decompensated cirrhosis cases within 2 years
03
Hepatic encephalopathy prevalence: 30-40% in cirrhosis patients
04
Variceal bleeding occurs in 30% of cirrhotics with portal hypertension
05
Spider angiomas seen in 33% of patients with compensated cirrhosis
06
Jaundice present in 20-30% at diagnosis of decompensated cirrhosis
07
Muscle wasting (sarcopenia) affects 40-70% of advanced cirrhosis patients
08
Pruritus reported in 20-50% of cholestatic cirrhosis cases
09
Palmar erythema in 15-25% of cirrhotics
10
Gynecomastia in 50-60% of male cirrhotics due to estrogen imbalance
11
Lower extremity edema in 50-60% of patients with ascites
12
Cognitive impairment (minimal HE) in 80% of cirrhotics awaiting transplant
13
Dupuytren's contracture in 20% of alcoholic cirrhotics
14
Testicular atrophy in 40-80% of men with alcoholic cirrhosis
15
Easy bruising/bleeding in 50-75% due to coagulopathy
16
Parotid gland enlargement in 25-35% of alcoholic cirrhotics
17
Asterixis (flapping tremor) in 30% during hepatic encephalopathy episodes
18
Caput medusae (umbilical hernia) in 15-20% with tense ascites
19
Fetor hepaticus in 10-20% of advanced cases
20
Ankle swelling as first symptom in 10% of cases
21
MELD score >15 correlates with 30-day mortality of 20%
22
FibroScan liver stiffness >12.5 kPa indicates cirrhosis with 87% accuracy
23
Serum AST/ALT ratio >1 suggests cirrhosis in alcoholic liver disease
24
Thrombocytopenia (<150,000/μL) in 76% of cirrhotics
25
ELF score >9.8 predicts advanced fibrosis/cirrhosis with 80% PPV
26
APRI score >2.0 has 76% specificity for cirrhosis detection
27
Low albumin (<3.5 g/dL) in 50% of decompensated patients
28
Elevated INR (>1.7) in 40% of Child-Pugh B/C patients
29
Ultrasound nodularity sensitivity 68-92% for cirrhosis
30
FIB-4 index >3.25 indicates cirrhosis with AUROC 0.84
Interpretation
Clinical Features Interpretation
In the clinical features of cirrhosis, fatigue is the most common symptom at 60 to 85% while decompensation complications are frequent with ascites in about 50% within 2 years, hepatic encephalopathy in 30 to 40%, and variceal bleeding in roughly 30% of patients with portal hypertension.
02 · Category
Epidemiology29 stats
01
Globally, cirrhosis accounts for 1.32% (1.27-1.37) of all deaths worldwide in 2017, equating to 1,320,000 deaths
02
In the US, the age-adjusted cirrhosis mortality rate increased from 9.2 per 100,000 in 2000 to 10.3 per 100,000 in 2015
03
Prevalence of cirrhosis in the general US adult population is estimated at 0.27% (688,000 persons)
04
In Europe, the incidence of cirrhosis hospitalization rates range from 20.2 to 134.0 per 100,000 population annually
05
Among US veterans, cirrhosis prevalence is 2.1% in 2018, up from 1.2% in 2008
06
In the UK, liver cirrhosis is the leading cause of liver-related death, with 60,000 hospital admissions in 2017-2018
07
Global prevalence of compensated cirrhosis is 0.3-1.5% in Western countries
08
In Brazil, cirrhosis mortality increased 33% from 2000 to 2017, reaching 14.6 per 100,000
09
US cirrhosis-related hospitalizations rose 54% from 326,000 in 2002 to 501,000 in 2015
10
In Japan, the age-adjusted mortality rate for cirrhosis declined from 22.3 per 100,000 in 1980 to 6.3 in 2017
11
Among US adults aged 45-64, cirrhosis prevalence is 1.0%
12
In India, cirrhosis contributes to 2.1% of total deaths, with alcohol being a major factor
13
EU cirrhosis prevalence estimated at 0.5-1% of adult population
14
In Australia, cirrhosis death rate is 12.4 per 100,000 in 2018
15
Global DALYs lost to cirrhosis: 35.9 million in 2017
16
In South Korea, cirrhosis incidence peaked at 78.6 per 100,000 in 2005, declining to 47.2 by 2019
17
US non-alcoholic fatty liver disease (NAFLD) cirrhosis prevalence: 4.3% in obese adults
18
In Canada, cirrhosis hospitalization rate: 135 per 100,000 in 2017
19
Worldwide, 80% of cirrhosis cases occur in low- and middle-income countries
20
In Mexico, cirrhosis is the third leading cause of death, with 25.6 per 100,000 rate in 2018
21
In the US, alcoholic cirrhosis mortality rate: 5.3 per 100,000 in 2019
22
Global hepatitis B-related cirrhosis prevalence: 15-40% of chronic carriers
23
In France, cirrhosis incidence: 34 per 100,000 person-years
24
US cirrhosis prevalence in Hispanics: 1.6%, higher than non-Hispanics at 0.2%
25
In China, cirrhosis affects 13 million people, mostly HBV-related
26
UK decompensated cirrhosis incidence: 21 per 100,000 annually
27
In Germany, cirrhosis mortality: 18.1 per 100,000 in 2016
28
Global HCV-related cirrhosis: 10-20% of chronic infections progress
29
In Sweden, cirrhosis prevalence: 0.4% in adults over 40
Interpretation
Epidemiology Interpretation
From an epidemiology standpoint, cirrhosis deaths are substantial worldwide at 1,320,000 in 2017, while in the US the age-adjusted mortality rate rose from 9.2 per 100,000 in 2000 to 10.3 per 100,000 in 2015, underscoring a growing health burden despite relatively low overall adult prevalence of 0.27%.
03 · Category
Etiology23 stats
01
Alcohol is responsible for 60% of cirrhosis cases in Western Europe
02
Chronic hepatitis C infection leads to cirrhosis in 20-30% of cases over 20-30 years
03
Non-alcoholic steatohepatitis (NASH) progresses to cirrhosis in 20% of cases
04
Heavy alcohol consumption (>30g/day women, >40g/day men) increases cirrhosis risk 5-fold
05
Hepatitis B chronic infection causes cirrhosis in 15-25% of untreated cases
06
Obesity (BMI >30) raises NASH-cirrhosis risk by 4.5 times
07
Type 2 diabetes increases cirrhosis risk 2.4-fold in NAFLD patients
08
Autoimmune hepatitis progresses to cirrhosis in 40-50% without treatment
09
Daily alcohol intake >60g for 20 years yields 30% cirrhosis risk
10
Metabolic syndrome components increase cirrhosis odds ratio by 3.2
11
Primary biliary cholangitis leads to cirrhosis in 20-30% over 10 years
12
HIV co-infection accelerates HCV-cirrhosis progression by 2-3 fold
13
Smoking increases alcoholic cirrhosis risk by 1.5-2 times
14
Insulin resistance is present in 90% of NASH-cirrhosis patients
15
Wilson's disease untreated leads to cirrhosis in 50% by age 20
16
Hemochromatosis causes cirrhosis in 20-30% of homozygotes
17
Alpha-1 antitrypsin deficiency ZZ genotype: 40% develop cirrhosis by age 50
18
Chronic hepatitis D superinfection worsens HBV cirrhosis risk to 70%
19
Female sex increases alcohol-induced cirrhosis risk at lower doses (OR 2.3)
20
Hypertriglyceridemia elevates NAFLD-cirrhosis risk by 2.7-fold
21
Celiac disease untreated raises cirrhosis risk 2-fold
22
Portal vein thrombosis risk in cirrhosis: 10-25% annually
23
Genetic polymorphisms (PNPLA3) increase NAFLD cirrhosis risk 3-6 fold
Interpretation
Etiology Interpretation
From an etiologic perspective, alcohol is the dominant driver of cirrhosis in Western Europe at 60% of cases and is also markedly risk increasing, with heavy consumption boosting cirrhosis risk by about fivefold.
More related reading
04 · Category
Management23 stats
01
Abstinence from alcohol improves survival by 2-fold in alcoholic cirrhosis
02
Beta-blockers reduce variceal bleeding risk by 40-50%
03
Diuretics (spironolactone + furosemide) control ascites in 90% initially
04
Lactulose reduces hepatic encephalopathy recurrence by 50%
05
TIPS shunt effective for refractory ascites in 75% of cases
06
DAA therapy cures HCV in >95%, preventing cirrhosis progression in 90%
07
Nutritional support (1.2-1.5g/kg protein) improves outcomes in 70%
08
Endoscopic band ligation controls acute variceal bleed in 80-90%
09
Vaccination against HBV prevents cirrhosis in high-risk groups 95% effective
10
Rifaximin as add-on to lactulose reduces HE breakthrough by 58%
11
Large-volume paracentesis relieves ascites symptoms in 100%, but recurs in 90%
12
Pioglitazone in NASH cirrhosis slows fibrosis in 45% responders
13
LT4 supplementation for subclinical hypothyroidism improves MELD in 60%
14
Albumin infusion post-paracentesis prevents circulatory dysfunction in 80%
15
Tenofovir for HBV cirrhosis suppresses viral load in 90% at 48 weeks
16
Exercise training improves sarcopenia muscle mass by 2-5% in trials
17
Proton pump inhibitors reduce bacterial translocation risk but increase infection 1.3-fold
18
Ursodeoxycholic acid stabilizes PBC cirrhosis in 40-50%
19
Statins safe and reduce mortality by 40% in compensated cirrhosis
20
Obeticholic acid improves fibrosis in 46% of NASH patients
21
Liver transplantation 1-year survival: 90-95% for cirrhosis
22
Carvedilol more effective than propranolol for varices (64% vs 35% HR reduction)
23
Enteral nutrition vs parenteral reduces infections by 50% in acute-on-chronic liver failure
Interpretation
Management Interpretation
Effective management strategies for cirrhosis markedly improve outcomes, including doubling survival with alcohol abstinence and reducing complications such as variceal bleeding risk by 40 to 50% and hepatic encephalopathy recurrence by 50%.
05 · Category
Outcomes23 stats
01
5-year mortality in decompensated cirrhosis is 50-70%
02
Hepatocellular carcinoma (HCC) develops in 1-8% annually in cirrhotics
03
1-year survival post-variceal bleed: 65% without rebleeding control
04
Refractory ascites 1-year mortality: 40-50%
05
Child-Pugh A cirrhosis 1-year survival: 95-100%
06
MELD score 40: 3-month mortality 71.3%
07
Spontaneous bacterial peritonitis (SBP) mortality: 20-30% per episode
08
Post-TIPS encephalopathy occurs in 25-35%, mortality unchanged
09
Alcoholic hepatitis on cirrhosis: 1-month mortality 30-50%
10
Acute-on-chronic liver failure 28-day mortality: 38%
11
HCC surveillance detects tumors at early stage in 60%, improving survival
12
Hepatorenal syndrome type 1 median survival: 2 weeks without treatment
13
Overt HE grade 3-4: 1-year mortality 42%
14
Post-paracentesis circulatory dysfunction in 20%, increases mortality
15
Liver transplant for NASH cirrhosis: 5-year survival 75%
16
Varices prevalence 40%, bleed risk 5-15% per year untreated
17
Child-Pugh C 1-year survival: 45%
18
Recidivism post-transplant for alcohol: 11-38% at 5 years
19
Portal vein thrombosis worsens survival by 20-30%
20
Compensated cirrhosis median survival: >12 years
21
SBP recurrence 68% within 1 year without prophylaxis
22
HCC in HBV cirrhosis: annual incidence 2-5%
23
Decompensated cirrhosis to transplant waitlist mortality: 20% at 3 months
Interpretation
Outcomes Interpretation
Overall, cirrhosis outcomes vary dramatically by disease severity, with 5-year mortality in decompensated cases reaching 50 to 70 percent and MELD 40 predicting a 71.3 percent 3-month mortality, while compensated Child-Pugh A patients fare far better with 95 to 100 percent 1-year survival.
report visual · Comparison
Cirrhosis: prevalence, progression, and outcomes
Cirrhosis is common, often presents with frequent complications, and can lead to substantial short- and long-term mortality.
5-year mortality in decompensated cirrhosis is 50-70%-70%
1-year survival post-variceal bleed: 65% without rebleeding control65%
Acute-on-chronic liver failure 28-day mortality: 38%38%
Post-TIPS encephalopathy occurs in 25-35%, mortality unchanged-35%
Prevalence of cirrhosis in the general US adult population is estimated at 0.27% (688,000 persons)0.27%
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Elif Demirci. (2026, February 13). Cirrhosis Statistics. Gitnux. https://gitnux.org/cirrhosis-statistics
MLA
Elif Demirci. "Cirrhosis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/cirrhosis-statistics.
Chicago
Elif Demirci. 2026. "Cirrhosis Statistics." Gitnux. https://gitnux.org/cirrhosis-statistics.
Sources & references
15 datasets cited across this report · attribution is report-level